Every Form 4 that Tg Therapeutics Inc (TGTX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow TGTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TGTX filings page.
TG Therapeutics director Laurence N. Charney reported three bona fide gifts of Common Stock totaling 6,050 shares on August 6–7, 2026. The shares were transferred at $0.00 per share to a 501(c)(3) institution, and he retains no beneficial ownership or pecuniary interest in the gifted stock. Remaining holdings are noted as including restricted Common Stock that vests over time.
Lonial Sagar reported acquisition or exercise transactions in this Form 4 filing.
TG Therapeutics director Sagar Lonial received a grant of 8,325 stock tracking units. Each unit is a contingent right to either one share of common stock or a cash payment equal to the fair market value of one share, generally within 30 days after the first anniversary of grant. The units vest on that first anniversary if he remains in continuous service, and this filing shows 8,325 units held after the grant.
HUME DANIEL reported acquisition or exercise transactions in this Form 4 filing.
TG Therapeutics director Daniel Hume reported a compensation grant of 8,325 Stock Tracking Units (STUs). Each STU is a contingent right to receive either one share of common stock or a cash payment equal to the fair market value of one share, no later than 30 days after the first anniversary of the grant date. The STUs vest on the first anniversary only if he remains in continuous service with the company, and he now holds 8,325 STUs directly.
Hoberman Kenneth reported acquisition or exercise transactions in this Form 4 filing.
TG Therapeutics director Kenneth Hoberman received an equity-based award tied to the company’s stock. He was granted 8,325 Stock Tracking Units on June 11, 2026, each linked to one share of common stock.
Each unit represents a contingent right, at the board committee’s discretion, to deliver either one share of common stock or a cash payment equal to the fair market value of one share, no later than 30 days after the first anniversary of the grant date. The units will vest on the first anniversary of the grant, provided he remains in continuous service with the company through that date.
Echelard Yann reported acquisition or exercise transactions in this Form 4 filing.
TG Therapeutics director Yann Echelard received a grant of 8,325 stock tracking units as equity compensation. Each unit represents a contingent right to receive either one share of common stock or a cash payment equal to the fair market value of one share. The committee administering the company’s 2022 Incentive Plan will choose stock or cash, and settlement must occur within 30 days after the first anniversary of the grant date. The units vest on the first anniversary of grant if Echelard remains in continuous service with the company.
TG Therapeutics director Laurence N. Charney received a grant of 8,325 Stock Tracking Units on June 11, 2026. These units were awarded as compensation and carry no exercise price.
Each Stock Tracking Unit represents a contingent right, at the discretion of the plan committee, to receive either one share of TG Therapeutics common stock or a cash payment equal to the fair market value of one share. This payment or share delivery is scheduled no later than 30 days after the first anniversary of the grant date, provided Charney remains in continuous service through that vesting date.
Following this award, Charney holds 8,325 Stock Tracking Units directly, each tied to an equivalent number of underlying common shares. The transaction does not involve any open-market buying or selling, and reflects a routine equity-based incentive grant.
TG Therapeutics director Laurence N. Charney reported two bona fide gifts of the company's Common Stock to his children. He gifted 30,000 shares on 01/28/2026 and 13,197 shares on 01/29/2026, both at a reported price of $0 per share.
After these gifts, Charney beneficially owned 192,887 shares and then 179,690 shares of Common Stock, held directly. This amount includes shares of restricted stock that vest over various time periods. The gifts were structured so he does not retain beneficial ownership or pecuniary interest in the transferred shares.
TG Therapeutics reported that CEO and director Michael S. Weiss received a grant of 622,000 shares of restricted common stock on January 8, 2026. The shares were granted at a price of $0 per share and are subject to performance-based vesting. They will vest on the first anniversary of the date on which the company’s total shareholder return first exceeds the return of the Nasdaq Biotechnology Index over a 3-, 5-, 7-, or 9-year period. Following this award, Weiss beneficially owned 9,778,086 shares of common stock, including other restricted shares that vest over various time periods.
TG Therapeutics CFO Sean A. Power reported an equity grant. On 01/08/2026 he was awarded 90,000 shares of TG Therapeutics common stock at a price of $0 per share, reported as an acquisition of non-derivative securities.
These are restricted shares, with one quarter scheduled to vest on each of 01/01/2027, 01/01/2028, 01/01/2029, and 01/01/2030. After this grant, he beneficially owns 798,111 shares of common stock, including restricted shares that vest over various time periods, all held directly.
TG Therapeutics director reports stock sale to cover taxes
A director of TG Therapeutics, Inc. (TGTX), Yann Echelard, reported a sale of company common stock. On 11/24/2025, 5,000 shares of TG Therapeutics common stock were sold at a price of $32.57 per share, as shown in Table I of the filing. The explanation states that these shares were sold by the company’s restricted stock administrator to satisfy Mr. Echelard’s income tax obligations.
After this transaction, Mr. Echelard beneficially owned 223,816 shares of TG Therapeutics common stock in direct form, which includes shares of restricted common stock that vest over various time periods.
TG Therapeutics (TGTX) CEO and director Michael S. Weiss filed a Form 4 reporting non-sale transfers of common stock. On 11/05/2025, he reported a distribution of 3,865,126 shares upon termination of the Michael Sean Weiss 2022 Grantor Retained Annuity Trust to irrevocable trusts for the benefit of his children, and a transfer of 803,717 shares to The Weiss Family and Descendants Trust. Both transactions were coded “G” and priced at $0 per share.
Following these transactions, Mr. Weiss beneficially owned 9,156,086 shares of TG Therapeutics common stock. The filing notes that this total includes shares of restricted stock that vest over various time periods.